Medtronic plc (MDT) EPS Estimated At $1.11

August 12, 2018 - By Sonya McDaniel

Medtronic plc (NYSE:MDT) LogoInvestors sentiment increased to 1.08 in Q1 2018. Its up 0.06, from 1.02 in 2017Q4. It improved, as 80 investors sold Medtronic plc shares while 383 reduced holdings. 88 funds opened positions while 414 raised stakes. 1.04 billion shares or 0.00% more from 1.04 billion shares in 2017Q4 were reported.
Stratos Wealth Prns reported 0.06% stake. Ipswich Management Company invested in 3,172 shares or 0.11% of the stock. Moreover, Novare Capital Management Lc has 1.29% invested in Medtronic plc (NYSE:MDT) for 92,101 shares. Florida-based Finemark Bancorp Trust has invested 0.14% in Medtronic plc (NYSE:MDT). Gam Holdg Ag holds 72,423 shares or 0.21% of its portfolio. Amica Pension Fund Board Of Trustees has invested 0.64% in Medtronic plc (NYSE:MDT). Capital Advisers Ltd Liability Corp holds 0.33% or 536,381 shares in its portfolio. Founders Mgmt Lc has invested 2.52% in Medtronic plc (NYSE:MDT). Triangle Wealth holds 0.44% of its portfolio in Medtronic plc (NYSE:MDT) for 9,540 shares. Qs Invsts Limited Liability Corp reported 72,968 shares. Martin & Incorporated Tn stated it has 22,017 shares or 0.59% of all its holdings. North Star Inv Mngmt invested in 0.06% or 5,943 shares. Hardman Johnston Global Advisors Limited Liability Corp has invested 1.09% of its portfolio in Medtronic plc (NYSE:MDT). Salem Invest Counselors Incorporated has invested 0.01% in Medtronic plc (NYSE:MDT). Nelson Roberts Invest Advisors Ltd Liability Com owns 0% invested in Medtronic plc (NYSE:MDT) for 115 shares.

Analysts expect Medtronic plc (NYSE:MDT) to report $1.11 EPS on August, 21 before the open.They anticipate $0.01 EPS change or 0.89 % from last quarter’s $1.12 EPS. MDT’s profit would be $1.50B giving it 20.41 P/E if the $1.11 EPS is correct. After having $1.42 EPS previously, Medtronic plc’s analysts see -21.83 % EPS growth. The stock decreased 0.68% or $0.62 during the last trading session, reaching $90.6. About 3.44 million shares traded. Medtronic plc (NYSE:MDT) has risen 0.84% since August 13, 2017 and is uptrending. It has underperformed by 11.73% the S&P500.

Medtronic plc (NYSE:MDT) Ratings Coverage

Among 8 analysts covering Medtronic (NYSE:MDT), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Medtronic had 11 analyst reports since February 21, 2018 according to SRatingsIntel. The firm has “Buy” rating by Citigroup given on Thursday, February 22. As per Thursday, May 24, the company rating was maintained by Needham. The stock of Medtronic plc (NYSE:MDT) has “Buy” rating given on Wednesday, February 21 by Needham. The firm has “Market Perform” rating by William Blair given on Wednesday, June 6. The rating was maintained by Morgan Stanley on Friday, May 25 with “Equal-Weight”. The rating was maintained by Morgan Stanley with “Equal-Weight” on Thursday, March 29. The rating was maintained by Bank of America on Thursday, May 24 with “Buy”. The rating was initiated by Piper Jaffray with “Buy” on Friday, April 27. Bank of America maintained it with “Buy” rating and $9800 target in Wednesday, June 6 report.

Medtronic plc manufactures and sells device medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company has market cap of $122.47 billion. The company's Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It has a 39.91 P/E ratio. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases.

More news for Medtronic plc (NYSE:MDT) were recently published by: Globenewswire.com, which released: “Medtronic Begins Pilot Study of Investigational Extravascular ICD System” on August 09, 2018. Seekingalpha.com‘s article titled: “FDA OKs Medtronic’s implantable system for Remodulin” and published on July 31, 2018 is yet another important article.

Medtronic plc (NYSE:MDT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.